LUCAR-DKS1 NK cells
Phase 1Cell therapy
LUCAR-DKS1 NK cells is one of 48 biologic programs targeting Autoimmune Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
74 competitors in Autoimmune Disease
#DrugCompanyPhaseTrials
1Atgam
NovartisPhase 2
Cytosar
TevaPhase 2
Rayos
RRoxane Laboratories
Phase 2
Alkeran
AApotex Inc.
Phase 2
Vepesid
AAvyxa
Phase 2
Bicnu
MMelissa K Accordino
Phase 2
Fludara
SanofiPhase 1
Rituxan
RochePhase 1
CAR-T Cell
PPersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
Anti-CD19 CAR-T Cells
TThe Children's Hospital of Zhejiang University School of Medicine
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LUCAR-DKS1 NK cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- NNanjing Legend Biotech Co.